234 related articles for article (PubMed ID: 20484020)
1. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers.
Harrington KJ; Karapanagiotou EM; Roulstone V; Twigger KR; White CL; Vidal L; Beirne D; Prestwich R; Newbold K; Ahmed M; Thway K; Nutting CM; Coffey M; Harris D; Vile RG; Pandha HS; Debono JS; Melcher AA
Clin Cancer Res; 2010 Jun; 16(11):3067-77. PubMed ID: 20484020
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.
Karapanagiotou EM; Roulstone V; Twigger K; Ball M; Tanay M; Nutting C; Newbold K; Gore ME; Larkin J; Syrigos KN; Coffey M; Thompson B; Mettinger K; Vile RG; Pandha HS; Hall GD; Melcher AA; Chester J; Harrington KJ
Clin Cancer Res; 2012 Apr; 18(7):2080-9. PubMed ID: 22316603
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.
Vidal L; Pandha HS; Yap TA; White CL; Twigger K; Vile RG; Melcher A; Coffey M; Harrington KJ; DeBono JS
Clin Cancer Res; 2008 Nov; 14(21):7127-37. PubMed ID: 18981012
[TBL] [Abstract][Full Text] [Related]
4. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.
Morris DG; Feng X; DiFrancesco LM; Fonseca K; Forsyth PA; Paterson AH; Coffey MC; Thompson B
Invest New Drugs; 2013 Jun; 31(3):696-706. PubMed ID: 22886613
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer.
Lolkema MP; Arkenau HT; Harrington K; Roxburgh P; Morrison R; Roulstone V; Twigger K; Coffey M; Mettinger K; Gill G; Evans TR; de Bono JS
Clin Cancer Res; 2011 Feb; 17(3):581-8. PubMed ID: 21106728
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.
White CL; Twigger KR; Vidal L; De Bono JS; Coffey M; Heinemann L; Morgan R; Merrick A; Errington F; Vile RG; Melcher AA; Pandha HS; Harrington KJ
Gene Ther; 2008 Jun; 15(12):911-20. PubMed ID: 18323793
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.
Roulstone V; Khan K; Pandha HS; Rudman S; Coffey M; Gill GM; Melcher AA; Vile R; Harrington KJ; de Bono J; Spicer J
Clin Cancer Res; 2015 Mar; 21(6):1305-12. PubMed ID: 25424857
[TBL] [Abstract][Full Text] [Related]
8. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.
Gollamudi R; Ghalib MH; Desai KK; Chaudhary I; Wong B; Einstein M; Coffey M; Gill GM; Mettinger K; Mariadason JM; Mani S; Goel S
Invest New Drugs; 2010 Oct; 28(5):641-9. PubMed ID: 19572105
[TBL] [Abstract][Full Text] [Related]
9. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.
Li JL; Liu HL; Zhang XR; Xu JP; Hu WK; Liang M; Chen SY; Hu F; Chu DT
Gene Ther; 2009 Mar; 16(3):376-82. PubMed ID: 19092859
[TBL] [Abstract][Full Text] [Related]
11. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.
Villalona-Calero MA; Lam E; Otterson GA; Zhao W; Timmons M; Subramaniam D; Hade EM; Gill GM; Coffey M; Selvaggi G; Bertino E; Chao B; Knopp MV
Cancer; 2016 Mar; 122(6):875-83. PubMed ID: 26709987
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.
Qiao J; Wang H; Kottke T; White C; Twigger K; Diaz RM; Thompson J; Selby P; de Bono J; Melcher A; Pandha H; Coffey M; Vile R; Harrington K
Clin Cancer Res; 2008 Jan; 14(1):259-69. PubMed ID: 18172278
[TBL] [Abstract][Full Text] [Related]
14. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials involving the oncolytic virus, reovirus: ready for prime time?
Black AJ; Morris DG
Expert Rev Clin Pharmacol; 2012 Sep; 5(5):517-20. PubMed ID: 23121273
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.
Forsyth P; Roldán G; George D; Wallace C; Palmer CA; Morris D; Cairncross G; Matthews MV; Markert J; Gillespie Y; Coffey M; Thompson B; Hamilton M
Mol Ther; 2008 Mar; 16(3):627-32. PubMed ID: 18253152
[TBL] [Abstract][Full Text] [Related]
17. Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling.
McEntee G; Kyula JN; Mansfield D; Smith H; Wilkinson M; Gregory C; Roulstone V; Coffey M; Harrington KJ
Oncotarget; 2016 Jul; 7(30):48517-48532. PubMed ID: 27384486
[TBL] [Abstract][Full Text] [Related]
18. Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03.
Tsien C; Moughan J; Michalski JM; Gilbert MR; Purdy J; Simpson J; Kresel JJ; Curran WJ; Diaz A; Mehta MP;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):699-708. PubMed ID: 18723297
[TBL] [Abstract][Full Text] [Related]
19. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
20. Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.
Bernstock JD; Bag AK; Fiveash J; Kachurak K; Elsayed G; Chagoya G; Gessler F; Valdes PA; Madan-Swain A; Whitley R; Markert JM; Gillespie GY; Johnston JM; Friedman GK
Hum Gene Ther; 2020 Oct; 31(19-20):1132-1139. PubMed ID: 32657154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
